

International Application No.PCT/EP00/00623 Dr.Carola Dony



## New Claims

- 1. A pharmaceutical composition containing a melanoma inhibiting activity factor and a biocompatible and/or biodegradable matrix selected from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxylapatite, polylactic-coglycolid, polyanhydrides, collagen, or combinations of these.
- 2. A pharmaceutical composition containing a melanoma inhibiting activity factor (MIA) in combination with an osteoinductive protein.
- 3. A pharmaceutical composition as claimed in claim 2, wherein the ratio of osteoinductive protein: MIA is 1:1 to 1:20.
- 4. A pharmaceutical composition as claimed in claim 2 or 3, wherein the osteoinductive protein is BMP-2, BMP-7 or a hedgehog protein.
- 5. A pharmaceutical composition as claimed in claims 2 to 4, wherein the composition includes a biocompatible matrix.
- 6. A pharmaceutical composition as claimed in claim 1 or 5, wherein the biocompatible matrix is hyaluronic acid, alginate, collagen, heparin, polylactic-coglycolid and/or polylactic-coglycolid derivatives or combinations thereof.
- 7. Use of a melanoma inhibiting activity factor (MIA) as the essential component for manufacturing a pharmaceutical composition for improved induction of the chondro-/osteogenic lineage and promotion of cartilage and or bone formation.

2



- 8. A use according to claim 7, wherein the composition contains in addition an osteoinductive protein.
- 9. A use as claimed in claim 8, wherein the osteoinductive protein is BMP-2 or BMP-7 or a hedgehog protein.
- 10. A use as claimed in claim 8 or 9, wherein the ratio of osteoinductive protein: MIA is 1:1 to 1:20.
- 11. A use as claimed in claims 8 to 10, wherein the melanoma inhibiting activity factor (MIA) is combined with a biocompatible matrix.
- 12. A method as claimed in claim 11, wherein the biocompatible matrix is hyaluronic acid, alginate, collagen, heparin, polylactic-coglycolid and/or polylactic-coglycolid derivatives or combinations thereof.
- 13. Use of an expression vector for a melanoma inhibiting activity factor (MIA) or a combination of a vector for the expression of an osteoinductive protein with a vector capable of expression of a melanoma inhibiting activity factor (MIA) for manufacturing a pharmaceutical composition for improved induction of the chondro-/osteogenic lineage and promotion of cartilage and/or bone formation.
- 14. A use of an expression vector capable of expression of a melanoma inhibiting activity factor (MIA) or a vector capable of expression of an osteoinductive protein and a vector capable of expression of a melanoma inhibiting activity factor (MIA) as essential component for manufacturing a pharmaceutical composition for improved induction of the chondro-/osteogenic lineage and promotion of cartilage and/or bone formation.

ART 34 Ame

3

- 15. A use as claimed in claim 13, wherein the composition includes a biocompatible matrix selected from the group consisting of hyaluronic acid, alginate, calcium sulfate, tricalcium phosphate, hydroxylapatite, polylactic-coglycolid, polyanhydrides, collagen, or combinations of these.
- 16. The use of a melanoma inhibiting activity factor (MIA) for the treatment of a patient in need of bone and/or cartilage repair.
- 17. The use according to claim 18, wherein a combination of a melanoma inhibiting activity factor (MIA) and an osteoinductive protein is used.

Printed:09-01-2001

AMENDED SHEET